Cargando…

GREM1 is a novel serum diagnostic marker and potential therapeutic target for pancreatic ductal adenocarcinoma

OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant neoplasm with rising incidence worldwide. Gremlin 1 (GREM1), a regulator of bone morphogenetic protein (BMP) signaling, fine-tunes extensive biological processes, including organ morphology, cellular metabolism, and multiple pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Sen, Zhang, Yalu, Hua, Yuze, Cui, Ming, Wang, Mengyi, Gao, Junyi, Liu, Qiaofei, Liao, Quan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458890/ https://www.ncbi.nlm.nih.gov/pubmed/36091126 http://dx.doi.org/10.3389/fonc.2022.968610

Ejemplares similares

Comprehensive Analysis of Expression, Prognostic Value, and Immune Infiltration for Ubiquitination-Related FBXOs in Pancreatic Ductal Adenocarcinoma
por: Zhang, Yalu, et al.
Publicado: (2022)

Up‐regulation of CDHR5 expression promotes malignant phenotype of pancreatic ductal adenocarcinoma
por: Gao, Junyi, et al.
Publicado: (2020)

Knockdown of LRRN1 inhibits malignant phenotypes through the regulation of HIF-1α/Notch pathway in pancreatic ductal adenocarcinoma
por: Zhang, Yalu, et al.
Publicado: (2021)

Upregulated CD58 is associated with clinicopathological characteristics and poor prognosis of patients with pancreatic ductal adenocarcinoma
por: Zhang, Yalu, et al.
Publicado: (2021)

Comprehensive analysis of mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs): A SEER database analysis of 767 cases
por: Song, Huixin, et al.
Publicado: (2023)

Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Origin, Polarization, Function, and Reprogramming
por: Yang, Sen, et al.
Publicado: (2021)

Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma
por: Zhao, Juan, et al.
Publicado: (2022)

CXCL5 overexpression predicts a poor prognosis in pancreatic ductal adenocarcinoma and is correlated with immune cell infiltration
por: Zhang, Ronghua, et al.
Publicado: (2020)

Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
por: Mehta, Shreya, et al.
Publicado: (2021)

Corrigendum: Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
por: Mehta, Shreya, et al.
Publicado: (2021)

Targeting mTOR in Pancreatic Ductal Adenocarcinoma
por: Iriana, Sentia, et al.
Publicado: (2016)

Non-coding RNAs in Pancreatic Ductal Adenocarcinoma
por: Gong, Ruining, et al.
Publicado: (2020)

Relevance of Immune Infiltration and Clinical Outcomes in Pancreatic Ductal Adenocarcinoma Subtypes
por: Liu, Rong, et al.
Publicado: (2021)

The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy
por: Principe, Daniel R., et al.
Publicado: (2021)

High Expression of Cancer-Derived Glycosylated Immunoglobulin G Predicts Poor Prognosis in Pancreatic Ductal Adenocarcinoma
por: Cui, Ming, et al.
Publicado: (2020)

Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review
por: Wang, Yizhi, et al.
Publicado: (2020)

Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma
por: Hayashi, Hiromitsu, et al.
Publicado: (2021)

Pancreatic Ductal Adenocarcinoma Cortical Mechanics and Clinical Implications
por: Angstadt, Shantel, et al.
Publicado: (2022)

The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma
por: Zhang, Jingchang, et al.
Publicado: (2022)

High Expression of Cancer-Derived Glycosylated Immunoglobulin G Predicts Poor Prognosis in Pancreatic Ductal Adenocarcinoma: Erratum
por: Cui, Ming, et al.
Publicado: (2021)

Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
por: Awad, Seifeldin, et al.
Publicado: (2020)

Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape
por: Xu, He, et al.
Publicado: (2021)

The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives
por: Wu, Yang, et al.
Publicado: (2021)

Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker
por: Song, Byeong Geun, et al.
Publicado: (2021)

Development and Validation of a Nomogram Based on Nutritional Indicators and Tumor Markers for Prognosis Prediction of Pancreatic Ductal Adenocarcinoma
por: Li, Haoran, et al.
Publicado: (2021)

Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study
por: Striefler, Jana Käthe, et al.
Publicado: (2021)

Identification of an unfolded protein response-related signature for predicting the prognosis of pancreatic ductal adenocarcinoma
por: Fang, Lishan, et al.
Publicado: (2023)

Computed Tomography-Based Radiomics Signature for the Preoperative Differentiation of Pancreatic Adenosquamous Carcinoma From Pancreatic Ductal Adenocarcinoma
por: Ren, Shuai, et al.
Publicado: (2020)

Possible Molecular Markers for the Diagnosis of Pancreatic Ductal Adenocarcinoma
por: Shen, Quan, et al.
Publicado: (2018)

A Simple Model Established by Blood Markers Predicting Overall Survival After Radical Resection of Pancreatic Ductal Adenocarcinoma
por: Zhang, Li-xiang, et al.
Publicado: (2020)

Robotic Versus Laparoscopic Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis
por: Feng, Qingbo, et al.
Publicado: (2021)

Vascularization, Oxygenation, and the Effect of Sunitinib Treatment in Pancreatic Ductal Adenocarcinoma Xenografts
por: Gaustad, Jon-Vidar, et al.
Publicado: (2019)

Systematic Characterization of the Clinical Relevance of KPNA4 in Pancreatic Ductal Adenocarcinoma
por: Bao, Jingpiao, et al.
Publicado: (2022)

Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?
por: Wang, Chenqi, et al.
Publicado: (2022)

Development and validation of an MRI-radiomics nomogram for the prognosis of pancreatic ductal adenocarcinoma
por: Xu, Xinsen, et al.
Publicado: (2023)

CD58 Immunobiology at a Glance
por: Zhang, Yalu, et al.
Publicado: (2021)

The enigmatic helicase DHX9 as a candidate prognostic biomarker for resected pancreatic ductal adenocarcinoma
por: Chen, Le-gao, et al.
Publicado: (2022)

Identification of Novel Molecular Therapeutic Targets and Their Potential Prognostic Biomarkers Among Kinesin Superfamily of Proteins in Pancreatic Ductal Adenocarcinoma
por: Yang, Yang, et al.
Publicado: (2021)

Immune subtyping for pancreatic cancer with implication in clinical outcomes and improving immunotherapy
por: Liu, Jingkai, et al.
Publicado: (2021)

Genome-Wide Profiling Reveals the Landscape of Prognostic Alternative Splicing Signatures in Pancreatic Ductal Adenocarcinoma
por: Yang, Chengkun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2d6qv285jsu9ubu4otlo8cupot